<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127046</url>
  </required_header>
  <id_info>
    <org_study_id>DW6008-I-1</org_study_id>
    <nct_id>NCT03127046</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers</brief_title>
  <acronym>DW6008</acronym>
  <official_title>A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the drug-drug interaction between aceclofena and esomeprazole
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, 3-way crossover study to evaluate the drug-drug
      interaction between Aceclofenac 200 mg and Esomeprazole 20 mg in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">April 23, 2017</completion_date>
  <primary_completion_date type="Actual">April 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 24hours</time_frame>
    <description>Maximum concentration of aceclofenac and esomeprazole in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 24hours</time_frame>
    <description>Area under the plasma concentration versus time curve to last time of aceclofenac and esomeprazole in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 24hours</time_frame>
    <description>Terminal half-time of aceclofenac and esomeprazole in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 24hours</time_frame>
    <description>Time to reach Cmax of aceclofenac and esomeprazole in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 24hours</time_frame>
    <description>Apparent clearance of aceclofenac and esomeprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>up to 24hours</time_frame>
    <description>Apparent volume of distribution of aceclofenac and esomeprazole</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aceclofenac</intervention_name>
    <description>Oral single dose administration of aceclofenac 200mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Airtal tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Oral single dose administration of aceclofenac 200mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Nexium tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aceclofenac and Esomeprazole</intervention_name>
    <description>Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Airtal and Nexium concomitant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy man over 19 years old

          -  Body Mass Index(BMI)=17.5~30.5kg/m2, one with weight of more than 55kg (BMI= kg/(m)2)

          -  Congenital or chronic diseases within the last three years, there is no medical
             examination results of popular characters with no psychotic symptoms or findings

          -  Depending on the nature of the drug your doctor check conducted hematology, blood
             chemistry, urinalysis and laboratory tests, including an electrocardiogram(EKG)
             performed during screening tests such as a suitable test subjects who judged

          -  The purpose of the test participants prior to testing, information, and to hear about
             the free will fully explain to participate in this study, according to the
             Institutional Review Board(IRB)-approved consent form signed by the parties in writing

        Exclusion Criteria:

          -  one with clinically significant blood, kidneys, endocrine, respiratory,
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or
             allergic disease (but ,except for untreated seasonal allergies of asymptomatic at the
             time of administration) with medical history or evidence

          -  one with gastrointestinal disease(Such as esophageal stricture or achalasia of the
             esophagus disease, Crohn disease) to affect drug absorption or surgery(but, excluding
             simple appendectomy or hernia surgery) with medical history

          -  Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 2 times the upper
             limit of the normal range

          -  Within 6 months, 210 g / week of alcohol in excess of a history of regular characters
             (beer (5%) 1 cup (250 mL) = 10 g, soju(20%) 1 cup (50 mL) = 8 g, Wine (12%) 1 cup (125
             mL) = 12 g)

          -  Take part in other clinical trials within three months

          -  Systolic Blood Pressure(SBP) ≥ 140 mmHg or Diastolic Blood Pressure (DBP) ≥ 90 mmHg

          -  The great history of alcohol or drug abuse within 1 year

          -  Taking medication of drug-metabolizing enzymes that are known to significantly induce
             or inhibit within 30 days

          -  More than 20 cigarettes a day smoker

          -  Taking medication of a prescription drug or nonprescription within 10 days,

          -  Within two months the whole blood donation have, within one month of the apheresis
             donation have

          -  Participate in clinical trials to test drug administration and may be at increased
             risk due to interpretation of test results, or may interfere with severe supply /
             chronic medical or mental condition or abnormal laboratory test values in character
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital in Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital.</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Aceclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

